Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03249792
Recruitment Status : Recruiting
First Posted : August 15, 2017
Last Update Posted : April 10, 2020
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when administered via intratumoral (IT) injection as monotherapy and in combination with pembrolizumab (MK-3475) intravenous (IV) infusion and via subcutaneous (SC) injection in combination with pembrolizumab IV infusion in the treatment of adult participants with advanced/metastatic solid tumors or lymphomas.

Condition or disease Intervention/treatment Phase
Solid Tumor Lymphoma Drug: MK-2118 (IT) Drug: MK-2118 (SC) Biological: Pembrolizumab Phase 1

Detailed Description:

Participants will receive either MK-2118 monotherapy or MK-2118 in combination with pembrolizumab for up to 35 cycles (approximately 2 years).

All participants will undergo an at least 24-hour observation period following the first three administrations of MK-2118 (Cycle 1 Days 1, 8 and 15).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 135 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Actual Study Start Date : September 20, 2017
Estimated Primary Completion Date : April 28, 2022
Estimated Study Completion Date : April 28, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Arm 1: MK-2118 IT Monotherapy
Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
Drug: MK-2118 (IT)
IT injection

Experimental: Arm 2: MK-2118 IT+Pembro Combo Therapy
Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
Drug: MK-2118 (IT)
IT injection

Biological: Pembrolizumab
IV infusion
Other Name: MK-3475

Experimental: Arm 3: MK-2118 Visceral IT+Pembro Combo Therapy
Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
Drug: MK-2118 (IT)
IT injection

Biological: Pembrolizumab
IV infusion
Other Name: MK-3475

Experimental: Arm 4: MK-2118 SC+Pembro Combo Therapy
Participants receive MK-2118 monotherapy via SC injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1, 8 and 15, for a total of up to 35 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 35 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.
Drug: MK-2118 (SC)
SC injection

Biological: Pembrolizumab
IV infusion
Other Name: MK-3475




Primary Outcome Measures :
  1. Dose-limiting Toxicities (DLTs) [ Time Frame: Arms 1, 2 & 3: Cycle 1 (Up to 21 days); Arm 4: Cycles 1 & 2 (Up to 35 days) ]
    A DLT is defined as the following toxicities, if related to study treatment: Grade 4 nonhematologic toxicity; Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia (Grade 4 thrombocytopenia of any duration, Grade 3 thrombocytopenia with clinically significant bleeding); Non-hematologic adverse event (AE) ≥Grade 3 (with exceptions); Grade 3 or Grade 4 nonhematologic abnormality; Febrile neutropenia Grade 3 or 4; Any toxicity that causes treatment discontinuation or causes participant to miss ≥1 dose during the DLT period; Any toxicity that causes a >2 week delay in initiation of Cycle 2; Any elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value that is ≥3× upper limit of normal (ULN) & an elevated total bilirubin value that is ≥2× ULN & an alkaline phosphatase value that is <2× ULN with no alternative explanation; Any ≥Grade 2 immune-mediated uveitis; Grade 5 toxicity. The number of participants who experience a DLT will be presented.

  2. Adverse Events (AEs) [ Time Frame: Up to approximately 28 months ]
    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be reported.


Secondary Outcome Measures :
  1. MK-2118 Minimum Plasma Concentration (Cmin) [ Time Frame: Cycle 1 Day 1: Predose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours postdose; Cycle 2 Day 1: Predose and 0.5, 1, 2, 4, 6 and 8 hours postdose ]
    The observed Cmin of MK-2118 when administered as monotherapy and in combination therapy with pembrolizumab will be determined.

  2. MK-2118 Maximum Plasma Concentration (Cmax) [ Time Frame: Cycle 1 Day 1: Predose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours postdose; Cycle 2 Day 1: Predose and 0.5, 1, 2, 4, 6 and 8 hours postdose ]
    The observed Cmax of MK-2118 when administered as monotherapy and in combination therapy with pembrolizumab will be determined.

  3. MK-2118 Area Under the Concentration-time Curve from 0 to 24 hours (AUC 0-24hr) [ Time Frame: Cycle 1 Day 1: Predose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours postdose ]
    The AUC 0-24hr of MK-2118 when administered as monotherapy and in combination therapy with pembrolizumab will be determined.

  4. Pembrolizumab Cmin [ Time Frame: Cycle 1 Day 1: Predose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours postdose; Cycle 2 Day 1: Predose and 0.5, 1, 2, 4, 6 and 8 hours postdose; Cycle 4 Day 1 and every 4 cycles thereafter (up to 35 cycles): Predose and 0.5, 1, 2, 4, 6 and 8 hours postdose ]
    The observed Cmin of pembrolizumab when administered as combination therapy with MK-2118 will be determined. This assessment will be performed only on participants in the MK-2118+Pembro combination therapy arms.

  5. Pembrolizumab Cmax [ Time Frame: Cycle 1 Day 1: Predose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours postdose; Cycle 2 Day 1: Predose and 0.5, 1, 2, 4, 6 and 8 hours postdose; Cycle 4 Day 1 and every 4 cycles thereafter (up to 35 cycles): Predose and 0.5, 1, 2, 4, 6 and 8 hours postdose ]
    The observed Cmax of pembrolizumab when administered as combination therapy with MK-2118 will be determined. This assessment will be performed only on participants in the MK-2118+Pembro combination therapy arms.

  6. Pembrolizumab AUC 0-24hr [ Time Frame: Cycle 1 Day 1: Predose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours postdose ]
    The AUC 0-24hr of pembrolizumab when administered as combination therapy with MK-2118 will be determined. This assessment will be performed only on participants in the MK-2118+Pembro combination therapy arms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Arms 1 and 2 Participants:

  • Has any histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report and has received, or have been intolerant to all treatment known to confer clinical benefit. Solid tumors and lymphomas of any type are eligible for enrollment. For cutaneous T-cell lymphoma (CTCL), histopathological diagnosis should be confirmed in a skin biopsy representative of disease.
  • Has Stage III or Stage IV disease that is not surgically resectable. Stage IIB (T3N0M0B0-1) CTCL participants are eligible.

Arm 3 Participants:

-Has metastatic liver and/or liver lesion involvement that does not exceed one third of the total liver volume in participants to be treated by liver IT injection. Hepatocellular carcinoma participants are excluded from eligibility of IT liver injection.

All Participants:

  • Has Stage III or Stage IV disease that is not surgically resectable.
  • Has ≥1 injectable lesion that is amenable to injection and biopsy via visual inspection for a cutaneous lesion, or via ultrasound guidance for a subcutaneous lesion.
  • Has ≥1 discrete, distant noninjected lesion that is amenable to biopsy via visual inspection or amenable to biopsy via image guidance.
  • Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Demonstrates adequate organ function.
  • If of childbearing potential, must agree to use adequate contraception during the treatment period and for at least 120 days after the last dose of study treatment.
  • Human Immunodeficiency Virus (HIV)-infected participants must meet these additional criteria:

    1. Has HIV-1 infection documented by laboratory test.
    2. Has well-controlled HIV on anti-retroviral therapy (ART), defined as: 1) must have a CD4+ T-cell count >350 cells/mm^3 at time of screening; 2) must have achieved and maintained virologic suppression defined as confirmed HIV ribonucleic acid (RNA) level <50 or below the lower limit of quantification (LLOQ) using the locally available assay at the time of screening and for ≥12 weeks prior to screening; and 3) must have been on a stable regimen, without changes in drugs or dose modification, for ≥4 weeks prior to study entry (Day 1).

Exclusion Criteria:

  • Has history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years (except for successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, or in situ cervical cancer).
  • Has clinically active central nervous system metastases and/or carcinomatous meningitis.
  • Has severe hypersensitivity reaction to treatment with a monoclonal antibody (mAb).
  • Has active autoimmune disease that has required systemic treatment in the past 2 years.
  • Has history of vasculitis.
  • Has active infection requiring therapy.
  • Has history of (noninfectious) pneumonitis that required steroids or current pneumonitis.
  • Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years.
  • Has known Hepatitis B or C infection.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
  • Is not fully recovered from any effects of major surgery, and is free of significant detectable infection.
  • HIV-infected participants with history of Kaposi's sarcoma and/or multicentric Castleman's disease.
  • HIV-infected participants who have had an HIV-related opportunistic infection within 6 months.
  • Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) prior to the first dose of study treatment, or has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 from the AEs due to cancer therapeutics administered >4 weeks earlier.
  • Has been treated within 2 weeks of Cycle 1 Day1 with any of the following: strong/moderate Cytochrome P450 2C9 (CYP2C9) inhibitors, such as: amiodarone, felbamate, fluconazole, miconazole, piperine, oxandrolone, fluorouracil and its derivatives (combination drug tegafur/gimeracil/oteracil [TS-1], Uftoral [UFT], tegafur, carmofur, doxifluridine, capecitabine), sulfaphenazole, cyclosporine, bucurol, tienilic acid; UGT1A3 inhibitors (including ritonavir, quinidine, probenecid, and valproic acid); or strong carbonyl reductase (CBR) inhibitors (including quercetin, menadione, glycyrrhetinic acid, and flufenamic acid).
  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and has received study therapy or has used an investigational device within 28 days of administration of MK-2118.
  • Is expected to require any other form of antineoplastic therapy while on study.
  • Is on chronic systemic steroid therapy in excess of replacement doses (prednisone ≤10 mg/day is acceptable), or on any other form of immunosuppressive medication. For CTCL, continued use of either prednisone ≤10 mg/day or continued use of topical steroids is acceptable.
  • Has received a live vaccine within 28 days prior to first dose.
  • Has been treated with a stimulator of interferon genes (STING) agonist (eg, MK-1454, ADU-S100 [synthetic cyclic dinucleotide (CDN)]).
  • Has a history of re-irradiation for SCCHN at the projected injection site.
  • Has a tumor(s) in direct contact or encases a major blood vessel and has ulceration and/or fungation onto the skin surface at the projected injection site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03249792


Contacts
Layout table for location contacts
Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com

Locations
Layout table for location information
United States, California
University of California San Diego Moores Cancer Center ( Site 0004) Recruiting
La Jolla, California, United States, 92093
Contact: Study Coordinator    858-822-7742      
UCLA ( Site 0003) Recruiting
Los Angeles, California, United States, 90095
Contact: Study Coordinator    310-794-6500      
United States, Illinois
University of Chicago ( Site 0002) Recruiting
Chicago, Illinois, United States, 60637
Contact: Study Coordinator    773-702-1152      
United States, New York
New York Presbyterian Hospital/Columbia University ( Site 0001) Recruiting
New York, New York, United States, 10032
Contact: Study Coordinator    646-317-5381      
United States, Texas
Mary Crowley Cancer Research Center ( Site 0005) Recruiting
Dallas, Texas, United States, 75230
Contact: Study Coordinator    214-658-1945      
MD Anderson Cancer Centr. ( Site 0006) Active, not recruiting
Houston, Texas, United States, 77030
Israel
Sheba Medical Center ( Site 0301) Recruiting
Ramat-Gan, Tell Abib, Israel, 5265601
Contact: Study Coordinator    +97235302542      
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT03249792    
Other Study ID Numbers: 2118-001
MK-2118-001 ( Other Identifier: Merck )
First Posted: August 15, 2017    Key Record Dates
Last Update Posted: April 10, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents